Corporate Strategy

• Advance to a Phase 1b clinical development trial of orally-administered Foralumab for the treatment of Crohn’s disease.
• Continue the IAP clinical development trial using intranasal administration of Foralumab (for neurodegenerative disease indication SPMS).
• Submit an IND for Anti-IL-6R (TZLS-501) monoclonal antibodies, in 3Q 2022.
• Explore the combination of milciclib and gemcitabine in NSCLC subjects with pan KRAS-positive mutations.
  
• Seek orphan drugs fast track or breakthrough designation for our product candidates where warranted.